Clinical trials: PET-CT
Glioblastomas
Feasibility Study of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT in Glioblastoma's Patients
This study is a non-randomized, prospective, multicentric feasibility study assessing 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT to differentiate early recurrence from post-radiation modifications in patients treated with radiotherapy…
- Trial name
- PAraDiGM (NCT03903419)
- Testing
- Feasibility study for the realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for identification of early recurrence in patients treated with radiotherapy for glioblastoma.
- Where
- 2 sites in France
- Volunteers
- 16 people
- Sponsor
- Centre Leon Berard
Malignant Tumor, Positron Emission Tomography
68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies.
- Conditions
- Malignant Tumor, Positron Emission Tomography, Fibroblast Activation Protein Inhibitor
- Trial name
- NCT06084767
- Testing
- 68Ga-TCR-FAPI PET/CT
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer
Use of Integrated PET/CT as a First Line Staging and Re-staging Technique in Oncologic Patient.
Positron emission tomoscintigraphy (PET) and contrast computed tomography (CTmdc) are diagnostic methods widely used in the staging and restaging of neoplastic diseases.
- Trial name
- NCT06168877
- Testing
- Execution of 18F-FDG PET/CT and contrast-enhanced CT scan.
- Volunteers
- 30 people
- Sponsor
- IRCCS San Raffaele
Inflammatory Rheumatism, 18-FDG
Diagnostic Performance of 18-FDG PET-CT Scores for the Diagnosis of Polymyalgia Rheumatica
Study of the diagnostic performance of 18-FDG PET scores in Polymyalgia rheumatica and comparaison with others inflammatories diseases.
- Conditions
- Inflammatory Rheumatism, 18-FDG, Positron-emission Tomography
- Trial name
- RHUMATEP (NCT06558357)
- Where
- France
- Volunteers
- 210 people
- Sponsor
- University Hospital, Brest
Prostate Cancer
Interest of Trimodality PET-CT Choline MRI Before Radiotherapy in High Risk Prostate Cancer
The initial staging of locally advanced prostate cancer is made with Computed Tomography scan (CT), Magnetic Resonance Imaging (MRI), and bone scan (BS).
- Trial name
- DEMETER (NCT03734757)
- Testing
- imaging in trimodality
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Henri Becquerel
Melanoma (Skin Cancer), Hepatocellular Carcinoma
68Ga-SorB PET/CT Imaging in Patients With Solid Tumors
This prospective, single-center, open-label exploratory diagnostic study aims to evaluate the safety, feasibility, and diagnostic performance of the novel Sortilin-targeted PET tracer 68Ga-SorB in patients with solid tumors.
- Conditions
- Melanoma (Skin Cancer), Hepatocellular Carcinoma, Lung Cancer, Breast Cancer
- Trial name
- SORB-PET (NCT07760012)
- Testing
- 68Ga-SorB PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University Third Hospital
Prostate Cancer, Prostate Neoplasm
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
The overall goal of this research is to validate and develop a non-invasive imaging biomarker of prostate cancer detection, progression, and recurrence.
- Trial name
- NCT03232164
- Testing
- 18F-DCFPyL PET
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Wisconsin, Madison
Malignant Tumors, Positron-Emission Tomography
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
This clinical trial aims to investigate the value of fibroblast activation protein PET/CT(PET/MR) in the diagnosis, staging, and evaluation of treatment outcomes in malignant tumors.
- Trial name
- NCT06270394
- Testing
- 68Ga-Fibroblast activation protein inhibitor
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Prostate Cancer
Study of 18F-Thretide PET/CT in Patients With Prostate Cancer
This study evaluates the diagnostic performance and safety of 18F-Thretide PET/CT in patients with biopsy proven prostate cancer who has no any form of therapy against prostate caner or suspected recurrence of prostate cancer who…
- Trial name
- NCT05516329
- Testing
- A single dose of 7±1 mCi (259±37 MBq) IV injection of 18F-Thretide
- Where
- China
- Volunteers
- 49 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Malignant Solid Tumors
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
This is the study of 64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.
- Trial name
- NCT05930457
- Testing
- 2.5-3.5mCi 64Cu-FAPI-XT117, 3.5-4.5mCi 64Cu-FAPI-XT117, 4.5-5.5mCi 64Cu-FAPI-XT117
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Prostate Cancer, Recurrence
Point in Time of Radiotherapy for Patients With Biochemical Recurrent Prostate Carcinoma
PSA-recurrence prostate carcinoma is associated with two general problems. 1. Localisation of PSA-recurrence is unconfident. In many cases it's not clear if a local, locoregional oder systemic relapse is available. 2.
- Trial name
- PROST-I (NCT02181192)
- Testing
- PET/CT, Instant Radiotherapy according to guidelines, Radiotherapy after achievement of PSA marginal value
- Volunteers
- 180 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
NSCLC
PET Response During Chemoradiation of Lung Cancer
A prospective observational study to determine the prognostic value of the timing of 50% reduction in metabolic activity (T50) during CCRT for NSCLC for treatment outcome (PFS).
- Trial name
- NCT02315053
- Testing
- Low dose FDG PET/CT 5 x.
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Neuroendocrine Tumors
PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
The aim of this non-randomised, prospective study is to investigate the applicability and prognostic value of uPAR PET/CT with the radioligand 68Ga-NOTA-AE105 in patients with neuroendocrine tumors (NETs).
- Trial name
- NCT03278275
- Testing
- One injection of 68Ga-NOTA-AE105, PET/CT
- Where
- Denmark
- Volunteers
- 116 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cervical Cancer, Endometrial Cancer
Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer
The purpose of this study is to see if a radioactive substance called 18F-Fluorodeoxyglucose (18F- FDG), injected into the cervix during a PET/CT scan done before surgery can show us more clearly which lymph nodes in the pelvis…
- Trial name
- NCT02285192
- Testing
- 18F-Fluorodeoxyglucose (18F-FDG), PET/CT imaging, PET/MRI imaging
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Small Cell Lung Cancer, Small Cell Lung Carcinoma
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
The purpose of this study is to look at how safe 89Zr-DFO-SC16.56 is, and how it is processed by the body in people with small cell lung cancer.
- Trial name
- NCT04199741
- Testing
- 89Zr-DFO-SC16.56, SC16.56, Phase I, Cohort 2, SC16.56, Phase I, Cohort 3
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Amyloidosis Cardiac
Multimodality Cardiac Imaging for Disease Progression in ATTR-CM
The goal of this clinical trial is to investigate whether new imaging techniques can help us to better understand the cardiac amyloidosis.
- Trial name
- FAPI-ATTR (NCT07112066)
- Testing
- FAPI tracer
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Dominik Benz
Prostate Cancer, Fluorocholine
18F-fluorocholine and 18F-fluoride PET in Prostate Cancer
Prostate cancer remains to be a public health problem around the world. For patients with prostate cancer, diphosphonate bone scintigraphy (BS) and pelvic tomographic imaging are major imaging tools to evaluate the disease…
- Trial name
- NCT04340765
- Testing
- 18F-fluorocholine
- Where
- Taiwan
- Volunteers
- 36 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Colorectal Cancer
64Cu/68Ga Labelled EB-ss-CPT PET/CT Scan in Colorectal Cancer
Positron labeled camptothecin based PET imaging is a new imaging technique that uses positron isotopes such as 68Ga/64Cu for PET/CT (MR) imaging.
- Trial name
- NCT05891028
- Testing
- 68Ga-EB-ss-CPT, 64Cu-EB-ss-CPT
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Peking Union Medical College Hospital
Neoplasms, Antioxidants
Oxidoreductive Balance and Lysosomal Activity in Cancer Patients.
The research aims to determine the parameters of oxidative stress and inflammatory processes and compare these parameters with the image obtained using positron emission tomography (PET) with 2-deoxy-2-[fluorine-18]fluoro…
- Conditions
- Neoplasms, Antioxidants, Oxidative Stress, Lipid Peroxidation
- Trial name
- NCT03470857
- Testing
- Patients
- Where
- 3 sites in Poland
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Nicolaus Copernicus University
Interstitial Lung Disease
Study Evaluating 68GA-FAPI-46 PET/CT in Patients With Interstitial Lung Disease
The purpose of this research is to better understand the distribution of an investigational radioactive imaging agent called 68Ga-FAPI-46 in the lungs of people with interstitial lung disease (ILD) during a Positron Emission…
- Trial name
- NCT07817563
- Testing
- ⁶⁸Ga-FAPI-46, PET/CT
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.